Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.

David KudrowJ Scott AndrewsMallikarjuna RettigantiTina OakesJennifer BardosCharly GaulRobert RiesenbergRichard WenzelDulanji KuruppuJames Martinez

Published in: Headache (2020)

Faster median time-to-first occurrence of response rates, lower frequency of pooled acute medications use, and a greater proportion of patients achieving a response anchored by patient-reported improvement were observed for galcanezumab vs placebo.

Keyphrases

patient reported
end stage renal disease
ejection fraction
newly diagnosed
risk assessment
phase iii
liver failure
double blind
randomized controlled trial
study protocol